Skip to Content

Photo Albums and Laboratory History

This page presents a visual archive of the Diamandis Laboratory and the Advanced Center for the Detection of Cancer (ACDC Lab). 

The photo albums document academic life, scientific collaboration, training activities, and institutional milestones associated with the laboratory over time.

The collection includes images from research meetings, scientific conferences, graduations, awards ceremonies, laboratory group activities, and professional collaborations. These materials are intended to provide historical and educational context for the laboratory’s research environment and academic community.


Dr. Eleftherios P. Diamandis currently serves as Division Head of Clinical Biochemistry at Mount Sinai Hospital, Biochemist-in-Chief at the University Health Network, and Professor and Head of Clinical Biochemistry in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Ontario, Canada. His research focuses on the discovery, validation, and clinical translation of biomarkers, with particular emphasis on cancer biology, proteomics, mass spectrometry, and translational biomedical research. Dr. Diamandis earned a B.Sc. in Chemistry, a Ph.D. in Analytical Chemistry, and an M.D. from the University of Athens, Greece, followed by a Diploma in Clinical Biochemistry from the University of Toronto. He is certified as a Clinical Chemist by both the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry.

Eleftherios Diamandis


Dr. Eleftherios P. Diamandis currently serves as Division Head of Clinical Biochemistry at Mount Sinai Hospital, Biochemist-in-Chief at the University Health Network, and Professor and Head of Clinical Biochemistry in the Department of Laboratory Medicine and Pathobiology at the University of Toronto, Ontario, Canada.

His research focuses on the discovery, validation, and clinical translation of biomarkers, with particular emphasis on cancer biology, proteomics, mass spectrometry, and translational biomedical research.

Dr. Diamandis earned a B.Sc. in Chemistry, a Ph.D. in Analytical Chemistry, and an M.D. from the University of Athens, Greece, followed by a Diploma in Clinical Biochemistry from the University of Toronto. He is certified as a Clinical Chemist by both the Canadian Academy of Clinical Biochemistry and the American Board of Clinical Chemistry.

He serves on the scientific advisory and editorial boards of more than 45 peer-reviewed journals, including The Journal of Biological Chemistry, Cancer Research, Molecular Cancer Research, Journal of Clinical Oncology, Clinical Chemistry, and Journal of Proteome Research. His work has been recognized through numerous national and international awards.

Dr. Diamandis has authored an extensive body of scientific literature, including over 500 research articles, more than 100 review papers, four books, and 39 book chapters. 

His publications have received over 43,000 citations, with an H-index of 105. He is also the inventor of multiple issued and pending patents and has supervised numerous Master’s and Ph.D. theses.

The Government of Ontario, in Ontario’s Innovation Agenda (2010), recognized Dr. Diamandis as one of the most highly published and cited biomarker researchers worldwide.

 

Awards

Photographs documenting academic and scientific awards received by members of the Diamandis Laboratory in recognition of research excellence and contributions to biomedical science.

Research Focus and Scientific Themes

The research conducted under Dr. Diamandis’ leadership addresses a broad range of topics in human disease biology, with a primary emphasis on cancer, while also encompassing neurodegenerative, autoimmune, inflammatory, and reproductive disorders. The laboratory integrates basic research, cell biology, and translational studies within a unified research framework.

Key research areas include:

 

Translational and Therapeutic Research

Translational research efforts aim to identify clinically relevant biomarkers and therapeutic targets. Areas of investigation include:

  • Clinical applications of kallikreins as diagnostic or prognostic markers
  • Roles of kallikreins in non-malignant diseases such as neurodegeneration and skin disorders
  • Identification of additional non-kallikrein biomarkers for disease diagnosis and monitoring

In cancer therapeutics, high-throughput screening technologies are used to evaluate compounds from large chemical libraries. Screening of libraries such as Spectrum, Prestwick, and LOPAC has identified members of the cardiac glycoside family as potential anti-cancer agents, with ongoing work exploring synergistic therapeutic strategies.


Kallikrein Research

A major scientific focus of the laboratory is the study of kallikreins, a family of related serine proteases located on human chromosome 19q13.4. The laboratory has cloned and characterized numerous genes within this family and investigates their role in both malignant and non-malignant diseases.

Research topics include:

  • Kallikrein gene structure and regulation
  • Protein function and enzymatic activity
  • Physiological pathways and enzymatic cascades
  • Identification of kallikrein substrates
  • Gene rearrangements in cancer
  • Diagnostic and therapeutic applications
  • Interactions with Proteinase-Activated Receptors (PARs)

To support this work, the laboratory develops recombinant proteins, monoclonal antibodies, molecular and immunological assays, and applies mass spectrometry-based methods to identify novel targets and inhibitors


Male Infertility and Autoimmune Disease Research

Research in male infertility focuses on the proteomic analysis of seminal plasma and related biological fluids, conducted in collaboration with clinical specialists. Parallel studies investigate genomic, proteomic, and transcriptomic signatures associated with prostate cancer.

In the area of autoimmune and rheumatic diseases, proteomic approaches are used to identify biomarkers linked to conditions such as psoriasis, psoriatic arthritis, and systemic lupus erythematosus, in collaboration with national and international clinical researchers.


Neurodegeneration

Another research focus involves the identification of biomarkers for the early detection of neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. This work is carried out in collaboration with experts in neurology and laboratory medicine and aims to improve understanding of disease mechanisms and progression.